Download app or launch web version here:

Download the App From iTunes Download the App From Google Play Launch the Web Version

We want to hear from you. Tell us what you think here or leave a comment on the app's iTunes or Google Play page.

Lipid Manager helps clinicians reduce ASCVD risk by managing patients' LDL-C and triglycerides. The app guides clinicians through the lipid-lowering process by linking three tools – LDL-C Lowering Therapy, Statin Intolerance, and Hypertriglyceridemia – all based on ACC clinical policy.

Input individualized patient data to:

• Review customized lifestyle and statin initiation advice
• Assess patient-specific response to lipid-lowering therapy
• Determine when and which non-statin therapies should be considered and with what goals
• Recommend lifestyle intervention and pharmacological management of high-risk patients with persistent hypertriglyceridemia

Print or email yourself a detailed report of all assessments conducted within the app. Each tool within the app is designed to be used on its own or in combination to manage a patient's therapy throughout their continuum of care. This app's tools also include the American Heart Association's PREVENT™-ASCVD risk estimator for determining 10-year (and in some cases 30-year) risk as part of their internal treatment workflows.

Advice from the app is derived from official ACC clinical policy documents including the 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia. The Hypertriglyceridemia tool continues to utilize the 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients with Persistent Hypertriglyceridemia.

The information and recommendations in this app are meant to support clinical decision making. They are not meant to represent the only or best course of care or replace clinical judgment. Therapeutic options should be determined after discussion between the patient and their care provider.

Financial support for Lipid Manager was provided by Esperion. All content was independently developed with no sponsor involvement.

Search "Lipid Manager" on the web or in your app store to download the app for free.

References

• Blumenthal, R, Morris, P, Gaudino, M. et al. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. 2026. https://doi.org/10.1016/j.jacc.2025.11.016
• Social deprivation index (SDI). Robert Graham Center - Policy Studies in Family Medicine & Primary Care. (2018, November 5). Retrieved November 29, 2021, from https://www.graham-center.org/rgc/maps-data-tools/sdi/social-deprivation-index.html
• Virani, S, Morris, P, Agarwala, A. et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. JACC. 2021 Aug, 78 (9) 960–993. https://doi.org/10.1016/j.jacc.2021.06.011
• Eckel, R, Jakicic, J, Ard, J. et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC. 2014 Jul, 63 (25_Part_B) 2960–2984. https://doi.org/10.1016/j.jacc.2013.11.003

Predicting Risk of Cardiovascular Disease EVENTs equations (PREVENT™):
The PREVENT™ equations were developed by select members of the American Heart Association Cardiovascular-Kidney-Metabolic Scientific Advisory Group. The risk equations were derived and validated in a large, diverse sample of over 6 million individuals.

• Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENTTM) Equations. Circulation 2023. DOI: 10.1161/CIRCULATIONAHA.123.067626.
• Khan SS, Coresh J, Pencina MJ, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation 2023;148(24):1982-2004. DOI: 10.1161/CIR.0000000000001191.

The information derived from the use of PREVENT™ is based on PREVENT™ 1.0.0. Updates and future adaptations of PREVENT™ may yield different results and conclusions.

Disclaimer: The American College of Cardiology Foundation is an independent entity and is not affiliated with, endorsed by, sponsored by, or approved by American Heart Association ("AHA"). Use of the PREVENT™ risk model and related materials is pursuant to a license from AHA and does not imply any partnership or association.

App Screenshots